Healthcare >> Sector Roundtables >> March 18, 2002

Roundtable Forum: Pharmaceutical Industry

RICHARD R. STOVER joined Arnhold and S. Bleichroeder, Inc. in 1998, and is the firm's Global Pharmaceuticals Analyst, specializing in the pharmaceutical industry as well as the Biotechnology and Biopharmaceutical sectors. Mr. Stover founded Stover & Associates LLC and Stover Haley Burns, Inc., two firms that specialize in the Life Sciences industry. Before joining Arnold S. Bleichroeder, Mr. Stover worked for Alex. Brown & Sons, Inc., Smith Barney, Prudential-Bache Securities, E.F. Hutton & Co. and Mitchell Hutchins, Inc. He also served as Director of Investor Relations, among other positions, at Pfizer, Inc. He has been named five times as an Institutional Investor 'All America Runner-Up' in the pharmaceutical industry. He is a member of the AIMR and the NYSSA and is a past President of the Health Industry Analysts Group of New York. Mr. Stover holds an MBA in Finance from the New York University Graduate School of Business and a BS in Economics from the University of Pennsylvania. Profile
PETER WEN, Vice President at Credit Suisse Asset Management, is an Analyst focusing on healthcare companies. He joined the firm in 1999 from Lynch & Mayer, where he was a healthcare Analyst. Previously, he was a Principal at SPEC, an information systems consulting firm. Mr. Wen holds a BA in Biology from Harvard College and an MBA in Finance from the University of Pennsylvania's Wharton School. He is fluent in Mandarin Chinese. Profile
MARIOLA B. HAGGAR is President, General Partner and Portfolio Manager at Haggar Concord Partners, LP. Ms. Haggar was previously associated with Deutsche Banc Alex. Brown and Salomon Brothers as a Pharmaceutical Analyst. Prior to that she was employed at Kemper Securities Group, Inc., L.F. Rothschild and Unterberg, Towbin and began her career at Kidder Peabody & Co. in 1982. Ms. Haggar received a BA in Biochemistry from Cornell University and an MPH from Columbia University. Profile
MARIO CORSO is a Vice President at Leerink Swann & Company and a Senior Research Analyst. Prior to joining Leerink Swann in April 2000, he was associated with ABN AMRO, where he covered large cap pharmaceutical companies for the three years. Additional previous affiliations include Rodman and Renshaw, Copley Pharmaceuticals, and Scudder Investments. Mr. Corso has a BA in Economics from the University of Connecticut and an MBA from Northeastern University. Profile
ADAM GREENE is a Vice President at Dresdner Kleinwort Wasserstein. Prior to joining the firm, he was associated with Credit Lyonnais Securities, First New York Securities and Gruntal & Co. LLC. Mr. Greene ranked number four for Pharmaceutical Earnings Estimate Accuracy for the 2001 Wall Street Journal 'Best On The Street Analyst Survey.' He graduated from Lehigh University, where he earned a BS in Finance. Profile
TWST: Peter, what part have pharmaceuticals played in your

strategy at Credit Suisse Asset Management over the past 12


Mr. Wen: I would say we have been very selective in the